Connect with us

Business

Eli Lilly’s weight loss pill orforglipron clears its latest trial, paving way for approval

Published

on

Eli Lilly’s weight loss pill orforglipron clears its latest trial, paving way for approval


Eli Lilly Biotechnology Center is shown in San Diego, California, U.S. March 1, 2023.

Mike Blake | Reuters

Eli Lilly on Tuesday said its daily weight loss pill helped patients with obesity and Type 2 diabetes shed weight in a late-stage trial, meeting the study’s main goal and clearing the way for the company to file for approval of the drug globally. 

The treatment is inching closer to becoming a new, needle-free alternative in the highly lucrative market for weight loss and diabetes drugs called GLP-1s. More convenient pills could boost supply for the treatments and make them easier to access than the pricey weekly injections currently dominating the space. The Eli Lilly pill also would not come with dietary restrictions, in contrast to a similar oral treatment from chief rival Novo Nordisk.

Eli Lilly shares climbed more than 4% Tuesday.

The highest dose of the pill, orforglipron, helped patients lose 10.5% of their weight, or 22.9 pounds, on average at 72 weeks, compared to 2.2% weight loss among those who took a placebo. The drug’s weight loss in the study was 9.6% when analyzing all patients regardless of discontinuations.     

Eli Lilly’s pill met the trial’s other goals of helping patients lower their hemoglobin A1c, a measure of blood sugar levels. By the end of the study, most patients no longer met the criteria for Type 2 diabetes based on that metric. The rate of side effects and treatment discontinuations in the study, called ATTAIN-2, appeared to be generally consistent with two recent phase three trials on Eli Lilly’s drug.

Eli Lilly said it now has the full clinical trial data package required to file for approvals of the drug for chronic weight management with global regulators. The pharmaceutical giant expects to launch the pill around the world “this time next year,” CEO David Ricks told CNBC in early August

In an interview, Eli Lilly’s Chief Scientific Officer Daniel Skovronsky, said the pill had “unprecedented efficacy” in patients with obesity and Type 2 diabetes, who typically have a more difficult time losing weight compared to those without diabetes. Skovronsky said he hopes that diabetes patients will be able to use the pill earlier in their disease to slow down its progression. 

Existing GLP-1 injections have shown greater weight loss than Eli Lilly’s pill, but having an oral option that offers more than 10% for patients with both obesity and Type 2 diabetes is “actually very good, so that’s positive,” said Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women’s Hospital.

But she called it “concerning” that more patients – 10.6% of those on the highest dose – stopped taking the pill due to side effects compared with what has been seen in separate studies on the existing injections, Eli Lilly’s Zepbound and Novo Nordisk‘s Wegovy. Apovian said patients and their prescribers will have to weigh the risks and benefits of the pill and the injections when deciding which to take, including convenience, side effects and efficacy. 

The side effects of Eli Lilly’s pill were mainly gastrointestinal, such as nausea and vomiting, and were mild to moderate in severity. An estimated 23.1% of those who took the highest dose experienced vomiting, while 36.4% and 27.4% had nausea and diarrhea, respectively.

Around 20% of patients stopped taking the pill for any reason, which is roughly the same rate as the placebo group. Skovronsky said that reflects a combination of reasons apart from side effects. Those can include patients who wanted to stop participating in a trial because they were able to access another obesity medication, or those who didn’t lose enough weight because they were taking a lower dose of the drug.

But he said most patients stay on the drug, and said “the most important thing here is the scale of the opportunity,” referring to the number of people around the world could benefit from orforglipron. More than 100 million adults in the U.S. alone have obesity, according to Centers for Disease Control and Prevention data.

Apovian said she’s most excited about an oral option entering the market not because of how much weight loss it can promote, but rather its potential to expand access to obesity treatments, especially since a pill is much easier to manufacture than an injection. Apovian hopes Eli Lilly’s pill will be priced lower than injections — which cost roughly $1,000 per month before insurance — and receive broader insurance coverage.

Tuesday’s results are the third set of late-stage data the company has released on orforglipron this year. In April, the pill succeeded in a shorter phase three trial on diabetes patients without obesity.

Earlier this month, the drug also met the goals of a separate study on patients with obesity and not diabetes, but fell short of Wall Street’s expectations. The pill’s weight loss was higher in that trial compared to Tuesday’s data, but “that’s expected,” given the differences in patient populations, said Dr. Jaime Almandoz, medical director of the Weight Wellness Program at UT Southwestern Medical Center. 

Overall, some doctors have touted the pill’s weight loss in the trials, and some analysts say it will still be a viable competitor in the space due to factors such as its easier manufacturing and lack of dietary restrictions. 

“The convenience and specifically the lack of fasting requirements and water restrictions with orforglipron is likely one of the main differentiators when people think about other oral agents with similar effectiveness for weight change and A1C levels,” said Almandoz.

He said a pill creates additional opportunities for individualized patient care “where there’s more autonomy.”

For example, some people may be hesitant to take injections for weight loss, said Dr. Andrew Krafston, clinical associate professor at the division of metabolism, endocrinology and diabetes at the University of Michigan

“While this is a surmountable barrier for many, oral therapy aligns with traditional medication treatment and may have higher acceptability,” he said, adding that pills are less likely to be in short supply.

Detailed trial data

The trial followed more than 1,600 people, who were randomized to receive three different target doses of Eli Lilly’s pill or a placebo. Patients started at a lower dose of the drug and gradually increased it at four-week intervals to reach their final target dose. 

More than 50% of patients on the highest dose of Eli Lilly’s treatment lost at least 10% of their weight in the trial, while 28.4% of those participants lost at least 15%. Across the different groups, the company did not disclose how many patients lost at least 5% of their weight. 

Orforglipron “may not be the answer” for patients who are morbidly overweight, said Howard Weintraub, clinical director of the Center for the Prevention of Cardiovascular Disease at NYU Langone Heart. But he said, “for a lot of people who need to lose a fair amount of weight, losing 10% can make a big diference.”

Orforglipron lowered A1C by an average of 1.3% to 1.8% across different doses at 72 weeks, from a starting level of 8.1%. Around 75% of participants taking the highest dose achieved an A1C of 6.5% or less, which is at or below what the American Diabetes Association defines as diabetes. 

Eli Lilly’s pill also improved key cardiovascular risk factors.

“We now have study after study with GLP-1 agonists showing that they reduce very important outcomes, which is what I do every day as a preventive cardiologist,” Weintraub said. “I try my very best to prevent them from having heart attack, stroke and death.”

Eli Lilly’s pill works in a similar way to Wegovy, Ozempic and Novo Nordisk’s diabetes pill Rybelsus, targeting a gut hormone called GLP-1 to suppress a person’s appetite and regulate blood sugar. Novo Nordisk is also seeking approval of an oral version of Wegovy, which could come by year-end.

But unlike those three medications, Eli Lilly’s pill is not a peptide medication. That means it is absorbed more easily by the body and does not require dietary restrictions like Rybelsus or oral Wegovy does.



Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

Indias Real Estate Equity Inflows Jump 48 Pc In Q3 2025: Report

Published

on

Indias Real Estate Equity Inflows Jump 48 Pc In Q3 2025: Report


NEW DELHI: Equity investments in India’s real estate sector jumped 48 per cent year-on-year to $3.8 billion in the July-September period (Q3), a report said on Friday. This growth in inflow was primarily fuelled by capital deployment into land or development sites and built-up office and retail assets, according to the report by real estate consulting firm CBRE South Asia.

In the first nine months of 2025, the equity investments increased by 14 per cent on-year to $10.2 billion — from $8.9 billion in the same period last year.

The report highlighted that land or development sites and built-up office and retail assets accounted for more than 90 per cent of the total capital inflows during Q3 2025.

Add Zee News as a Preferred Source


On the category of investors, developers remained the primary drivers of capital deployment, contributing 45 per cent of the total equity inflows, followed by Institutional investors with a 33 per cent share.

CBRE reported that Mumbai attracted the highest investments at 32 per cent, followed by Pune at around 18 per cent and Bengaluru at nearly 16 per cent.

Anshuman Magazine, Chairman and CEO – India, South-East Asia, Middle East and Africa, CBRE, said that the healthy inflow of domestic capital demonstrates the sector’s resilience and depth.

“In the upcoming quarters, greenfield developments are likely to continue witnessing a robust momentum, with a healthy spread across residential, office, mixed-use, data centres, and I&L sectors,” he added.

In addition to global institutional investors, Indian sponsors accounted for a significant part of the total inflows.

“India’s ability to combine strong domestic capital with global institutional participation will remain a key differentiator in 2026 and beyond,” added Gaurav Kumar, Managing Director, Capital Markets and Land, CBRE India.

CBRE forecasts a strong finish for the investment activity in 2025, fuelled by capital deployment into built-up office and retail assets.

For the office sector, the limited availability of investible core assets for acquisition indicate that opportunistic bets are likely to continue gaining traction, the report noted.



Source link

Continue Reading

Business

EY and Microsoft launch AI skills passport: Free program to train youth in AI; focus on career growth – The Times of India

Published

on

EY and Microsoft launch AI skills passport: Free program to train youth in AI; focus on career growth – The Times of India


EY and Microsoft on Saturday launched the AI Skills Passport, a free online learning initiative aimed at equipping Indian students and early-career professionals with essential artificial intelligence (AI) skills. The program targets individuals aged 16 and above and is designed to bridge the country’s growing AI skills gap, according to an EY statement, ANI reported.Part of a global effort that has already engaged over 40,000 participants worldwide, the AI Skills Passport offers self-paced learning modules spanning around 10 hours, available in both English and Hindi. The curriculum covers AI fundamentals, responsible AI, and practical applications across sectors including healthcare, finance, and technology. Participants also receive guidance on job readiness, including resume tips, interview support, and networking insights.Learners who complete the program are awarded a verifiable digital badge, enhancing their professional profiles. The initiative is part of EY Ripples, EY’s global corporate responsibility programme, and will partner with not-for-profit organisations to ensure students from economically weaker backgrounds have access to mentorship, learning, and career guidance.Monesh Dange, Partner and Leader, Alliances and Ecosystems, EY India, said, “In an era where AI is revolutionising work, the AI Skills Passport addresses India’s urgent need for skilled talent. Together with Microsoft, we aim to ensure the program is accessible and impactful at scale.”Bhaskar Basu, Enterprise Partnerships Leader, Microsoft India & South Asia, added, “AI is transforming India’s digital economy, and youth are at its core. The AI Skills Passport brings high-quality AI learning to everyone, accelerating Microsoft’s goal to equip 10 million Indians with AI skills by 2030.”





Source link

Continue Reading

Business

Environment minister Bhupender Yadav heads to Brazil: India engages in pre-talks ahead of COP30; climate finance and adaptation on agenda – The Times of India

Published

on

Environment minister Bhupender Yadav heads to Brazil: India engages in pre-talks ahead of COP30; climate finance and adaptation on agenda – The Times of India


Union Environment Minister Bhupender Yadav is set to travel to Brasília on October 13-14 for a pre-COP meeting as India steps up preparations for the UN climate summit COP30, scheduled in Belém, Brazil, in November. The meeting aims to streamline negotiations on key issues and build consensus among ministers before the main conference. He confirmed his visit on his X account. The two-day pre-COP will bring together environment and climate ministers, senior negotiators, and observers to narrow differences on politically sensitive issues and build ministerial consensus ahead of the COP30 negotiations, PTI reported. The COP30 presidency expects 30-50 delegations and around 800 participants at the event.Pre-COPs, while not formal UNFCCC events, have become a routine instrument for host countries to focus ministerial attention on a limited set of political questions that otherwise take negotiators weeks to resolve. Ministers use these meetings to test negotiating texts, identify common ground, and prepare positions to expedite negotiations at the main COP.COP30 is unfolding against a complex geopolitical backdrop, with some developed countries reassessing climate strategies amid economic and energy security pressures. The United States’ withdrawal from the Paris Agreement has further heightened tensions. Disagreements over climate finance, the pace and responsibility of the energy transition, and burdens on developing countries remain sharp.Trust between developed and developing countries is fragile following COP29 in Baku, Azerbaijan, where many Global South delegates said finance outcomes fell short of expectations. Central issues include the scale and nature of climate finance, grant versus loan structures, and predictability of funds for adaptation and loss and damage. These topics are expected to dominate discussions in Brasília and later in Belém.Logistical concerns are adding further pressure. Reports indicate shortages of hotel rooms and high costs in Belém, potentially limiting participation of smaller delegations and vulnerable countries. Observers warn that unequal attendance could affect negotiating dynamics and the legitimacy of outcomes.Key discussion points include climate finance, the post-2025 collective finance goal, rules and integrity for international carbon trading under Article 6, adaptation and national adaptation plans, and translating the Global Stocktake into actionable timelines. Loss and damage finance will also be a priority, with ministers aiming to make it predictable and accessible.India has emphasised equity and differentiated responsibilities in climate action, urging developed countries to meet Article 9 obligations on finance. It has pressed for predictable and concessional support for adaptation and loss and damage, while highlighting the need for technology transfer and capacity building aligned with national circumstances. India has also underscored a just energy transition that allows space for development.Ahead of COP30, India plans to submit two key documents: an updated Nationally Determined Contribution (NDC), extending commitments to 2035, and the country’s first national adaptation plan (NAP). The updated NDC is expected to raise ambition on emissions intensity of GDP, non-fossil electricity capacity, and carbon sinks through forest and tree cover, without introducing new pledges. India has already exceeded its target for non-fossil installed capacity ahead of the 2030 deadline.Officials told PTI that India will closely monitor outcomes on carbon markets and accounting, ensuring that poorly designed rules do not shift burdens or create perverse incentives.





Source link

Continue Reading

Trending